Literature DB >> 15661533

OVCA1: tumor suppressor gene.

Chun-Ming Chen1, Richard R Behringer.   

Abstract

OVCA1, also known as DPH2L1, is a tumor suppressor gene associated with ovarian carcinoma and other tumors. Ovca1 homozygous mutant mice die at birth with developmental delay and cell-autonomous proliferation defects. Ovca1 heterozygous mutant mice are tumor-prone but rarely develop ovarian tumors. OVCA1 appears to be the homolog of yeast DPH2, which participates in the first biosynthetic step of diphthamide, by modification of histidine on translation elongation factor 2 (EF-2). Yeast dph2 mutants are resistant to diphtheria toxin, which catalyses ADP ribosylation of EF-2 at diphthamide. Thus, there appears to be growing evidence implicating alterations in protein translation with tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661533     DOI: 10.1016/j.gde.2004.12.006

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  12 in total

1.  The asymmetric function of Dph1-Dph2 heterodimer in diphthamide biosynthesis.

Authors:  Min Dong; Emily E Dando; Ilana Kotliar; Xiaoyang Su; Boris Dzikovski; Jack H Freed; Hening Lin
Journal:  J Biol Inorg Chem       Date:  2019-08-28       Impact factor: 3.358

2.  White spot syndrome virus open reading frame 222 encodes a viral E3 ligase and mediates degradation of a host tumor suppressor via ubiquitination.

Authors:  Fang He; Beau J Fenner; Andrew K Godwin; Jimmy Kwang
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 3.  The ubiquitin-proteasome system and chromosome 17 in cerebellar granule cells and medulloblastoma subgroups.

Authors:  Jerry Vriend; Hassan Marzban
Journal:  Cell Mol Life Sci       Date:  2016-09-03       Impact factor: 9.261

4.  DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.

Authors:  Katsuhiro Togami; Timothy Pastika; Jason Stephansky; Mahmoud Ghandi; Amanda L Christie; Kristen L Jones; Carl A Johnson; Ross W Lindsay; Christopher L Brooks; Anthony Letai; Jeffrey W Craig; Olga Pozdnyakova; David M Weinstock; Joan Montero; Jon C Aster; Cory M Johannessen; Andrew A Lane
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

5.  Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor.

Authors:  Sebastian Stahl; Ana Rita da Silva Mateus Seidl; Axel Ducret; Sabine Kux van Geijtenbeek; Sven Michel; Tomas Racek; Fabian Birzele; Alexander K Haas; Ruediger Rueger; Michael Gerg; Gerhard Niederfellner; Ira Pastan; Ulrich Brinkmann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

6.  Elongation factor 2 diphthamide is critical for translation of two IRES-dependent protein targets, XIAP and FGF2, under oxidative stress conditions.

Authors:  Sandro Argüelles; Simonetta Camandola; Roy G Cutler; Antonio Ayala; Mark P Mattson
Journal:  Free Radic Biol Med       Date:  2013-10-17       Impact factor: 7.376

7.  A dominant-negative approach that prevents diphthamide formation confers resistance to Pseudomonas exotoxin A and diphtheria toxin.

Authors:  Vincent Roy; Karim Ghani; Manuel Caruso
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.752

8.  Elp3 and Dph3 of Schizosaccharomyces pombe mediate cellular stress responses through tRNALysUUU modifications.

Authors:  Desirée Villahermosa; Oliver Fleck
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

9.  A mutated dph3 gene causes sensitivity of Schizosaccharomyces pombe cells to cytotoxic agents.

Authors:  Desirée Villahermosa; Karen Knapp; Oliver Fleck
Journal:  Curr Genet       Date:  2017-05-29       Impact factor: 3.886

10.  Silencing of diphthamide synthesis 3 (Dph3) reduces metastasis of murine melanoma.

Authors:  Lei Wang; Yu Shi; Peijun Ju; Rui Liu; Siok Ping Yeo; Yinyan Xia; Hamed Owlanj; Zhiwei Feng
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.